We are live on ! Find out more
VVM

Versant Venture Management Portfolio holdings

AUM $141M
1-Year Est. Return 190.82%
This Fund
S&P 500
This Quarter Est. Return
+51.11%
1 Year Est. Return
+190.82%
3 Year Est. Return
+375.7%
5 Year Est. Return
+81.85%
10 Year Est. Return
+4,735.29%
AUM
$98.7M
AUM Growth
-$39.8M
Cap. Flow
-$64.2M
Cap. Flow %
-65.04%
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
–
Reduced
1
Closed
2

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$44.4M
2
GKOS icon
Glaukos
GKOS
+$12.7M
3
BITI
BIOTIE THERAPIES CORP SPONSORED ADR
BITI
+$7.09M

Sector Composition

Rank Sector Weight
1 Healthcare 95.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GKOS icon
1
Glaukos
GKOS
$8.89B
$75.4M 76.45%
2,586,985
-549,247
-18% -$12.7M
OCUL icon
2
Ocular Therapeutix
OCUL
$1.85B
$11M 11.11%
2,215,384
– –
CLVS
3
DELISTED
Clovis Oncology, Inc.
CLVS
$5.59M 5.66%
407,416
– –
AKAO
4
DELISTED
Achaogen Inc
AKAO
$4.86M 4.92%
1,281,152
– –
CBAY
5
DELISTED
Cymabay Therapeutics
CBAY
$1.82M 1.85%
1,048,601
– –
FPRX
6
DELISTED
Five Prime Therapeutics, Inc.
FPRX
– –
-1,092,152
Closed -$44.4M
BITI
7
DELISTED
BIOTIE THERAPIES CORP SPONSORED ADR
BITI
– –
-268,672
Closed -$7.09M

Similar funds

POIA
Pin Oak Investment Advisors Houston, Texas $141M AUM 20.83% 1-Year Est. Return
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
TM
TFJ Management Somerville, Massachusetts $141M AUM 9.28% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
RB
Renasant Bank Tupelo, Mississippi $141M AUM 16.9% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
CFGW
Chancellor Financial Group WB Wilkes-Barre, Pennsylvania $141M AUM 23.22% 1-Year Est. Return

Versant Venture Management's Q2 2016 Portfolio in Review

As of Q2 2016, Versant Venture Management held 7 positions worth $98.7M, down 29% from $139M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Versant Venture Management withdrew a net $64.2M in Q2 2016, closing 2 positions and reducing 1 holding. Its most notable exit was Five Prime Therapeutics, Inc., an estimated $44.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 92% a quarter earlier.

  • Versant Venture Management's biggest Q2 2016 reduction was Glaukos, cutting an estimated $12.7M.
  • Versant Venture Management fully exited Five Prime Therapeutics, Inc. in Q2 2016, selling an estimated $44.4M.
  • Versant Venture Management's ten largest holdings make up 100% of its $98.7M portfolio in Q2 2016.
  • Versant Venture Management opened 0 new positions and closed 2 in Q2 2016.
  • Versant Venture Management's portfolio value fell 29% quarter-over-quarter to $98.7M.

Based on Versant Venture Management's 13F filing for Q2 2016, filed 28 Jul 2016.